9 Things to Know About Cabotegravir (Apretude)

Taking a pill every day works beautifully for many people. Remembering that pill every day, however, can be a different storyespecially when life starts juggling work, travel, relationships, and the mysterious disappearance of every phone charger you own.

Cabotegravir, sold under the brand name Apretude, offers another approach to HIV prevention. Instead of taking daily oral pre-exposure prophylaxis, or PrEP, eligible people receive a long-acting injection from a healthcare professional every two months after the initiation phase. When the schedule is followed correctly, injectable cabotegravir is highly effective at reducing the risk of sexually acquired HIV.

Apretude is convenient, but it is not a casual “get a shot and forget about it” medication. HIV testing, timely appointments, possible injection-site discomfort, drug interactions, and a careful plan for missed or discontinued doses all matter. Here are nine essential things to know before deciding whether cabotegravir PrEP fits your life.

1. Apretude is long-acting PrEP, not a complete HIV treatment

Apretude contains cabotegravir, an antiretroviral medication known as an integrase strand transfer inhibitor. HIV normally uses an enzyme called integrase to insert its genetic material into human immune cells. Cabotegravir interferes with that step, making it harder for the virus to establish an infection.

The important word here is prevention. Apretude is intended for people who do not have HIV and may be exposed to the virus through sex. It cannot be used by itself as treatment for someone who already has HIV. Cabotegravir is also included in Cabenuva, an injectable HIV treatment regimen, but Cabenuva contains an additional drug and serves a different purpose. Similar name, different job description.

The FDA approved Apretude for at-risk adults and adolescents who weigh at least 77 pounds, or 35 kilograms. Its approved indication focuses on reducing the risk of sexually acquired HIV-1.¹

2. HIV-negative status must be confirmed before every injection

HIV testing is not merely a box to check before the first dose. Apretude carries a boxed warning about the risk of drug-resistant HIV when it is given to someone with an undiagnosed infection. A person must be confirmed HIV-negative before starting cabotegravir PrEP and before each subsequent injection.

Current CDC guidance recommends laboratory testing with both an HIV antigen-antibody assay and an HIV-1 RNA test for people receiving injectable cabotegravir. The RNA test can help detect infection earlier than antibody testing alone, which is especially important because antiretroviral exposure may delay or blur typical test results.²

Report possible symptoms of acute HIV

Tell the clinic about any recent HIV exposure or flu-like symptoms, including fever, rash, fatigue, swollen lymph nodes, sore throat, muscle aches, or night sweats. These symptoms have many possible causes, but they may occasionally signal early HIV infection. If test results are unclear, the clinician will usually pause the injection and repeat testing rather than play laboratory roulette.

If HIV is confirmed, Apretude must be stopped and a complete HIV treatment regimen should be started promptly. Cabotegravir alone does not provide adequate HIV treatment.

3. The standard injection schedule has an initiation phase

Apretude is supplied as a 600-milligram extended-release suspension. A healthcare professional gives it as a deep intramuscular injection in the buttock. It is not a take-home injection and should not be self-administered.

The usual schedule includes:

• A first 600-milligram initiation injection
• A second 600-milligram injection one month later
• One 600-milligram maintenance injection every two months thereafter

An optional oral lead-in with 30 milligrams of cabotegravir once daily for approximately one month may be used before the first injection. This trial period can help assess tolerability, but it is not required for everyone.³

Patients should not assume full protection begins the moment the first needle leaves the room. Available guidance on the exact time required to achieve maximum protection is limited and may vary by exposure route and clinical situation. Ask the prescribing clinician whether temporary backup prevention is appropriate when beginning the regimen.

4. Cabotegravir PrEP is highly effective when appointments stay on schedule

According to the CDC, injectable cabotegravir is more than 99% effective at reducing the risk of acquiring HIV through sex when used as prescribed.² No prevention option is literally perfect, but these are impressive numbers by any reasonable standard.

Two major clinical trials helped establish its effectiveness. HPTN 083 enrolled cisgender men and transgender women who have sex with men. Long-acting cabotegravir produced substantially fewer HIV infections than daily oral tenofovir disoproxil fumarate/emtricitabine.⁴

HPTN 084 studied cisgender women in sub-Saharan Africa. In the primary analysis, four incident HIV infections occurred in the cabotegravir group, compared with 36 among participants assigned to daily TDF/FTC. Differences in adherence to daily tablets contributed to the real-world advantage seen with injections.⁵

These findings do not mean oral PrEP is weak. Daily oral PrEP is also extremely effective when taken consistently. The practical question is often which routine a person can maintain: one tablet every day or a clinic appointment every two months.

5. Injection-site reactions are common but usually manageable

The most frequently reported Apretude side effects involve the injection site. Pain, tenderness, swelling, redness, warmth, itching, bruising, or a small firm nodule may occur. Because the medication is injected into a large muscle as a three-milliliter suspension, the buttock may lodge a formal complaint afterward.

Most injection-site reactions in clinical trials were mild or moderate and improved within several days. Reactions also tended to become less frequent over time. Walking gently, avoiding intense gluteal exercise immediately after the injection, and using a warm or cold compress may help, provided the clinic approves.

Other reported side effects include:

• Headache
• Fatigue
• Fever
• Muscle or back pain
• Nausea or diarrhea
• Dizziness
• Sleep disturbances

Serious reactions are uncommon but require attention. Seek medical help for facial swelling, breathing difficulty, widespread rash, blistering, severe weakness, or other signs of an allergic reaction. Cabotegravir has also been associated with liver toxicity and depressive disorders in a limited number of patients. Yellowing of the skin or eyes, dark urine, persistent upper-abdominal pain, severe depression, or suicidal thoughts should be reported immediately.⁶

6. Missed injections require a plannot wishful thinking

The maintenance window generally allows an injection to be given up to seven days before or after the scheduled date. If an appointment will be missed by more than seven days, contact the clinic as early as possible. Depending on the timing, a clinician may prescribe oral cabotegravir temporarily or recommend another oral PrEP regimen.

When an injection is substantially overdue, the correct restart schedule depends on which dose was missed and how much time has passed. Some patients can receive the delayed dose and continue their existing schedule. Others need two initiation injections one month apart again. This is why copying a friend’s instructionsor asking a search engine to serve as an infectious-disease specialistis not a great strategy.

Before restarting, the healthcare provider must reassess possible HIV exposures, ask about symptoms, and perform appropriate HIV testing. If a recent exposure has already occurred while protection may have been inadequate, post-exposure prophylaxis, or PEP, may need to be considered urgently. PEP works best when started as soon as possible and no later than 72 hours after an exposure.⁷

7. Cabotegravir remains in the body long after injections stop

Apretude’s long duration is both its superpower and its administrative fine print. After the final injection, measurable cabotegravir can remain in the bloodstream for 12 months or longer. Drug levels gradually decline during a period commonly called the pharmacokinetic “tail.”

Eventually, concentrations may become too low to prevent HIV but remain high enough to encourage cabotegravir-resistant virus if infection occurs. People who discontinue Apretude and still anticipate HIV exposure generally need another effective prevention method. The CDC recommends starting oral PrEP within eight weeks after the last cabotegravir injection when ongoing protection is needed.

Follow-up does not end when the injections end. CDC guidance calls for HIV antigen-antibody and HIV-1 RNA testing every three months for 12 months after the final injection.² Think of stopping Apretude as a planned transition, not hitting an eject button while cruising down the highway.

8. Drug interactions and health conditions deserve a careful review

Cabotegravir is metabolized mainly through UGT1A1, with some contribution from UGT1A9. Certain medications accelerate these pathways and may reduce cabotegravir concentrations enough to weaken its preventive effect.

Apretude should not be combined with several strong enzyme-inducing drugs, including:

• Carbamazepine
• Oxcarbazepine
• Phenobarbital
• Phenytoin
• Rifampin
• Rifapentine

Rifabutin also affects cabotegravir, although specialized dosing adjustments may sometimes be possible under professional supervision. Give the prescriber a complete list of prescription drugs, over-the-counter products, vitamins, and herbal supplements. “Natural” does not mean invisible to the liver.

Kidney and liver considerations

Unlike tenofovir-based oral PrEP, injectable cabotegravir does not generally require routine kidney-function assessment. This can make it useful for some people with serious kidney disease who cannot use particular oral PrEP medications.

However, Apretude does not treat hepatitis B. Someone with chronic hepatitis B who switches from tenofovir-based PrEP to cabotegravir may need separate hepatitis B treatment and monitoring to prevent a flare. Liver tests may also be appropriate for people with liver disease or symptoms suggesting hepatotoxicity.

Pregnancy and breastfeeding

Available pregnancy and breastfeeding data for long-acting cabotegravir remain more limited than the evidence for TDF/FTC. Current U.S. guidance allows individualized consideration of cabotegravir when pregnancy is possible or occurs, but the benefits, uncertainties, and alternatives should be discussed with an HIV or prenatal-care specialist. TDF/FTC has the longest-established pregnancy safety record among PrEP options.⁸

9. Apretude prevents HIVnot other sexually transmitted infections

Cabotegravir PrEP does not prevent gonorrhea, chlamydia, syphilis, herpes, human papillomavirus, hepatitis C, or pregnancy. Condoms, recommended vaccines, regular STI screening, contraception when desired, and honest conversations with partners remain valuable parts of sexual healthcare.

Before starting PrEP, sexually active patients should be screened for gonorrhea, chlamydia, and syphilis. Continued screening is recommended at intervals based on sexual practices and individual risk. Testing sites may include blood, urine, the throat, rectum, vagina, or cervix; testing only urine can miss infections elsewhere.

PrEP should be offered without shame or assumptions. People may choose it because they have a partner whose HIV status is unknown, use condoms inconsistently, recently had an STI, have multiple partners, or simply want greater control over their health. The CDC recommends prescribing PrEP to sexually active people who request it, even when they do not disclose specific risk factors.²

Is Apretude better than daily oral PrEP?

Neither option wins for everyone. Apretude may be especially appealing to people who dislike daily medication, have difficulty taking pills consistently, want a discreet option, or cannot use tenofovir because of kidney problems. It also provides coverage that does not depend on remembering a tablet during travel, a stressful week, or an unexpectedly romantic Tuesday.

On the other hand, injections require reliable clinic access, frequent HIV RNA testing, insurance or assistance coordination, and comfort with gluteal injections. Daily oral PrEP may offer greater flexibility for people who travel often, cannot return every two months, prefer avoiding injections, or need a medication that also treats hepatitis B.

The most effective PrEP option is usually the medically appropriate one a person can use consistently. A candid conversation with an experienced clinician can help balance health history, exposure routes, schedule, privacy, pregnancy plans, medication interactions, and personal preference.

Experiences With Cabotegravir: What the Routine May Feel Like

The following examples are realistic composite scenarios created for education. They are not individual patient testimonials, and experiences vary.

Experience 1: Escaping the daily-pill reminder

Imagine Marcus, a 31-year-old restaurant manager whose work schedule changes more often than the specials board. He used oral PrEP successfully but sometimes could not remember whether he had taken his evening tablet. A pill organizer helped, as did phone alarms, until he started dismissing the alarms automaticallya surprisingly transferable human skill.

After discussing his options, Marcus chooses Apretude. His clinic performs HIV antigen-antibody and RNA testing, screens him for STIs, and reviews his medications. He skips the optional oral lead-in and receives his first injection.

His buttock feels sore that evening, particularly when sitting in the car. The discomfort resembles a strong post-workout ache and fades over three days. The second injection one month later causes less soreness. Marcus enjoys not storing PrEP pills at home, but he quickly learns that the new routine has simply traded daily adherence for calendar adherence. He schedules each visit before leaving the clinic and adds two reminders to his phone.

Experience 2: Managing travel around an injection

Elena, 27, travels for several months of contract work. Her maintenance injection is due in the middle of an out-of-state assignment. Instead of waiting until she is overdue, she calls the clinic several weeks ahead.

Her clinician explains the permitted dosing window and helps arrange an injection near her temporary location. If that had not been possible, an oral medication could have been considered as a bridge. The key is that the backup plan is made before her protection becomes uncertain.

This experience highlights a practical truth: Apretude can remove the daily pill burden, but it does not remove logistics. Transportation, laboratory turnaround times, insurance authorization, medication supply, and clinic scheduling all affect the routine. People who travel frequently may want to ask how the clinic handles early appointments, planned missed injections, records transfer, and oral bridging before committing to long-acting PrEP.

Experience 3: Deciding that injections are not the right fit

Consider Jordan, 24, who likes the idea of bimonthly PrEP but finds the first two injections unusually uncomfortable. The pain is not dangerous, yet it interferes with workouts and makes every hard chair feel personally insulting.

Jordan discusses the issue instead of silently disappearing from follow-up. The clinician checks for signs of infection or a serious reaction, reviews comfort measures, and explains that injection-site discomfort often decreases over time. Jordan tries one more maintenance dose but ultimately prefers oral PrEP.

The clinic creates a transition plan, starts an appropriate oral regimen within the recommended period, and schedules continued HIV testing during the cabotegravir tail. Switching is not failure. PrEP is preventive healthcare, not a loyalty program, and preferences may change.

Questions worth asking before the first injection

• Which HIV tests will be performed before each dose?
• What should I do if I develop flu-like symptoms after a possible exposure?
• How does the clinic manage planned travel or missed appointments?
• Will my medications or supplements interact with cabotegravir?
• What costs might remain after insurance or assistance programs?
• What is the plan if I decide to stop Apretude?
• Which STI tests and vaccinations are recommended for me?

Conclusion

Cabotegravir gives eligible people a highly effective way to prevent sexually acquired HIV without taking a pill every day. Its two-month maintenance schedule can improve convenience, privacy, and adherence, but success depends on timely injections and repeated HIV testing.

The biggest practical lessons are simple: confirm HIV-negative status before every dose, report symptoms or recent exposures, plan ahead for missed appointments, and never stop injections without arranging follow-up protection when HIV exposure remains possible. Apretude’s long pharmacokinetic tail makes the exit plan almost as important as the starting plan.

For the right person, long-acting PrEP can turn HIV prevention into six routine maintenance visits per year after initiation. For someone else, oral PrEP may remain easier. The best choice is the one that matches both medical needs and real lifebecause prevention works much better when the plan survives contact with your calendar.